1. Conroy MC, Bander NH and Lepow IH: Effect of intradermal injections in the rat of purified proteases from Streptococcus and Serratia marescens. Proc Soc Exp Biol Med 1975; 150:801-805.

2. Bander NH: Comparison of antigen expression of human renal cancer in vivo and in vitro. Cancer 1984; 53:1235-1239.

3. Cordon-Cardo C, Bander NH, Fradet Y, Finstad CL, Whitmore WF Jr, Lloyd KO, Oettgen HF, Melamed MR and Old LJ: Immunoanatomic dissection of the human urinary tract by monoclonal antibodies. J Histochem Cytochem 1984; 32:1035-1040.

4. Bander NH, Welt S, Houghton AN, Lloyd KO, Grando R, Yeh S, Whitmore WF Jr, Vaughan ED Jr, Oettgen HF and Old LJ: Radionuclide imaging of human renal cancer with labeled monoclonal antibodies. Surg Forum 1984; 35:652-655.

5. Bander NH: Renal cancer: A model system for the study of human neoplasia. In: Contributions in Oncology, Riethmuller G, Koprowski H, von Kleist S, (eds). S. Karger, Basel) 1984.

6. Finstad CL, Cordon-Cardo C, Bander NH, Whitmore WF Jr, Melamed MR and Old LJ: Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. Proc Natl Acad Sci USA 1985; 82:2955-2959.

7. Bander NH, Cordon-Cardo C, Finstad CL, Whitmore WF Jr, Vaughan ED Jr, Oettgen HF, Melamed MR and Old, LJ: Immunohistologic dissection of the human kidney using monoclonal antibodies. J Urol 1985; 133:502-505.

8. Bander NH: Study of the normal human kidney and kidney cancer with monoclonal antibodies. Uremia Invest 1985; 8:263-273.

9. Fleischmann J, Heston W, Bauer W, Ratliff T, Bander NH and Fair W: Human renal cell carcinoma xenograft morphology, growth and chemosensitivities. J Urol 1985; 134:570-574.

10. Bander NH and Cordon-Cardo C: Monoclonal antibody defined markers of human renal cancer. In: Monoclonal Antibodies to Tumor Markers, Sell S, Reisfeld R, (eds). Humana Press, Clifton, NJ, 1985.

11.Rosenberg S, Bander NH and Herr H: Testis tumors. In: Current Therapy in Endocrinology, Krieger D, Bardin W, (eds). BC Decker, Philadelphia, PA 1985.

12. Tolkoff-Rubin NE, Cosimi AB, Delmonico FL, Russell PS, Thompson RE, Piper DJ, Hansen WP, Bander NH, Finstad CL, Cordon-Cardo C, Klotz LH, Old and Rubin RH: Diagnosis of tubular injury in renal transplant patients by a urinary assay for a proximal tubular antigen, the adenosine-deaminase-binding protein. Transplantation 1986; 41:593-597.

13. Cordon-Cardo C, Lloyd KO, Finstad CL, McGroarty ME, Reuter VE, Bander NH, Old LJ and Melamed MR: Immunoanatomic distribution of blood group antigens in the human urinary tract. Influence of secretor status. Lab Invest 1986; 55:444-454.

14. Sternberg CN, Yagoda A, Bander NH, Whitmore WF Jr, Huffman JL, Fleisher M, Melamed MR, Fanucchi MP, Hollander P and Vaughan ED Jr: Phase I/II trial of intravesical methotrexate for superficial bladder tumors. Cancer Chemother Pharmacol 1986; 18:265-269.

15. Tolkoff-Rubin NE, Cosimi AB, Delmonico FL, Russell PS, Thompson RE, Piper DJ, Hansen WP, Bander NH, Finstad CL, Cordon-Cardo C, Klotz LH, Old LJ and Rubin RH: Monitoring of renal proximal tubular injury in transplantation with a monoclonal antibody-based assay for the adenosine deaminase-binding protein. Transplant Proc 1986; 18:716-718.

16. Bander NH: Monoclonal antibodies. In: American Urological Association Update, Ball TP Jr, Novick DE, (eds). AUA Office of Education, Houston, TX 1986.

17. Bander NH: Monoclonal antibodies and the diagnosis and treatment of bladder cancer. In: Bladder Cancer: Future Directions for Treatment, Yagoda A, (ed). John Wiley & Sons, NY, NY 1986.

18. Bander NH and Klotz LH: Tumor immunology: In: Urologic Oncology, Graham S Jr, (ed). Raven Press, NY, NY 1986.

19. Cordon-Cardo C, Finstad CL, Bander NH, Old LJ and Melamed MR: Immunoanatomic distribution of cytostructural and tissue-associated antigens in the human urinary tract. Am J Pathol 1987; 126:269-284.

20. Tolkoff-Rubin NE, Thompson RE, Piper DJ, Hansen WP, Bander NH, Cordon-Cardo C, Finstad CL, Klotz LH, Old LJ and Rubin RH: Diagnosis of renal proximal tubular injury by urinary immunoassay for a proximal tubular antigen, the adenosine deaminase-binding protein. Nephrol Dialysis Transplant 1987; 2:143-148.


21. Kantor RRS, Bander NH, Finstad CL, Graf LH Jr, Lloyd KO, Old LJ and Albino AP: DNA-mediated gene transfer of a human cell surface 170-kilodalton glycoprotein. Evidence for association with an endogenous murine protein. J Biol Chem 1987; 262:15166-15171.

22. Carter HB, Amberson JB, Bander NH, Badalment R, Gorelick J, Vaughan ED Jr and Whitmore WF Jr: Newer diagnostic techniques for bladder cancer. Urol Clin N Amer 1987; 14(4): 763-769.

23. Bander NH: Monoclonal antibodies: State of the art. J Urol 1987; 137: 603-612.

24. Klotz LH and Bander NH: Monoclonal antibodies and urologic oncology: Antigenic expression on genitourinary tumors. In: Genitourinary Cancer, Ratliff TL, Catalona WJ, (eds). Martinus Nijhoff Publishers, Boston, MA, 1987.

25. Weir EC, Insogna KL, Brownstein DG, Bander NH and Broadus AE: In vitro adenylate cyclase-stimulating activity predicts the occurrence of humoral hypercalcemia of malignancy in nude mice. J Clin Invest 1988; 81(3): 818-821.

26. Bander NH: Continent urinary diversion in the treatment of bladder cancer. New Developments in Medicine 1988; 2: 65-81.

27. Mangin M, Webb AC, Dreyer BE, Posillico JT, Ikeda K, Weir EC, Stewart AF, Bander NH, Barton DE, Francke U and Broadus AE: Identification of a complementary DNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. Proc Natl Acad Sci USA 1988; 85: 597-601.

28. Sternberg C, Yagoda A, Scher H, Watson R, Herr H, Morse M, Sogani P, Vaughan ED Jr, Bander NH, Weiselberg L, Geller N, Hollander P, Lipperman R, Fair WR and Whitmore WF Jr: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139: 461-469.

29. Ikeda K, Mangin M, Dreyer B, Webb A, Posillico J, Stewart A, Bander NH, Weir E, Insogna K and Broadus AE: Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNAs from a variety of human and animal tumors associated with humoral hypercalcemia of malignancy. J Clin Invest 1988; 81: 2010-2014.

30. Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, Bander NH, Geller N, Fair WR and Whitmore WF Jr: Chemotherapeutic management of invasive bladder carcinoma. Eur Urol 1988; 14 (suppl): 19-20.


31. Bander NH, Finstad CL, Cordon-Cardo C, Ramsawak RD, Vaughan ED Jr, Whitmore WF Jr, Oettgen HF, Melamed MR and Old LJ: Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets of renal cell carcinomas. Cancer Res 1989; 49: 6774-6780.

32. Sternberg C, Yagoda A, Scher HI, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, Bander NH et al.: M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. Cancer 1989; 64: 2448-2458.

33. Nanus DM, Ebrahaim SAD, Bander NH, Real FX, Pfeffer LM, Shapiro JR and Albino AP: Transformation of human kidney proximal tubule cells by ras-containing retroviruses. Implications for tumor progression. J Exp Med 1989; 169: 953-972.

34. Wang JCL, Walle A, Novogrodsky A, Suthanthiran M, Silver RT, Bander NH, Rubin AL and Stenzel KH: A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion of interleukin-2. J Clin Oncol 1989; 7: 1885-1891.

35. Yagoda A and Bander NH: Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 1989; 44: 338-345.

36. Bander NH: ed. Renal cell carcinoma. In: Seminars in Urology, vol 7, no 3, WB Saunders, Philadelphia, PA, 1989.

37. Ebert T and Bander NH: Kidney-derived cell lines. Seminars in Urology 1989; 7:247-251.

38. Bander NH: Monoclonal antibodies to renal cancer antigens. Seminars in Urology 1989; 7: 264-270.

39. Bander NH: Ureteral stent for nonrefluxing, continent urinary diversions reduces complications and hospitalization for patients. Urol 1990; 35: 64-67.

40. Nanus DM, Mentle IR, Motzer RJ, Bander NH and Albino AP: Infrequent ras oncogene point mutations in renal cell carcinoma. J Urol 1990; 143: 175-178.

41. Nanus DM, Pfeffer LM, Bander NH, Bahri S and Albino AP: Anti-proliferative and anti-tumor effect of alpha-interferon in renal carcinoma: correlation to the expression of kidney associated differentiation glycoprotein. Cancer Res 1990; 50: 4190-4194.

42. Ebert T, Bander NH, Finstad CL, Ramsawak RD and Old LJ: Establishment and characterization of renal cancer and normal kidney cell lines. Cancer Res 1990; 50: 5531-5536.

43. Rettig WJ, Triche TJ and Bander NH: Somatic cell genetic analysis of human cell surface antigens 5.1H11 and F35/9 (gp45). Genomics 1990; 6: 178-183.

44. Libby DM, Bander NH, Altorki NK, Gold J, Pitts WR Jr and Frankel SS: Simultaneous pulmonary and renal malignancy. Chest 1990; 98: 153-156.

45. Kerr L, Huntcoon C, Donohue J, Leibson PJ, Bander NH, Ghose T, Luner SJ, Vessella R and McKean DJ: Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells in in vitro activated lymphocytes. J Immunol 1990; 44: 4060-4067.

46. Bander NH: Monoclonal antibodies to renal cancer antigens. Eur Urol 1990; 18: 10-12.

47. Ebert T and Bander NH: Immunodiagnosis of renal cancer. In: Immunodiagnosis of Cancer, Mercer DW, Herberman RB, (eds). Marcel Dekker, New York, NY 1990
48. Sheinfeld J, Cordon-Cardo C and Bander NH: Immunodiagnosis of bladder cancer. In: Immunodiagnosis of Cancer, Mercer DW, Herberman RB, (eds). Marcel Dekker, New York, NY 1990.

49. Ebert T, Ackerman R and Bander NH: Biologische marker beim nierenzellkarzinom. Urologie 1990; 29: 65-70.

50. Gulmi FA and Bander NH: Managing carcinoma in situ of the bladder. Contemp Urol 1990; 1: 45-52.

51. Bander NH: Initial results with a slightly modified Koch pouch. Urol 1991; 37:100-105.

52. Gastl G, Finstad CL, Guarini A, Bosl G, Gilboa E, Bander NH and Gansbacher B: Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 1992; 52: 6229-6236.

53. Bander NH, Gastl G, Nanus DM, Pfeffer LM, Finstad CL and Albino AP: Anti-proliferative and anti-tumor effect of -interferon in renal cell carcinoma: Correlation with the expression of a kidney associated differentiation glycoprotein. In: Basic and Clinical Research on Renal Cell Carcinoma, Staehler G, Pomer S, (eds). Springer-Verlag, Heidelberg, Germany 1992.

54. Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn R, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, Oettgen HF and Old LJ: Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. J Clin Oncol 1993; 11: 738-750.

55. Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH and Rubin SC: High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Brit J Heamatol 1993; 83: 433-441.

56. Gastl G, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, Chen N, Albino AP and Bander NH: Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993; 55: 96-101.

57. Nanus DM, Engelstein D, Gastl GA, Gluck L, Vidal MJ, Morrison M, Finstad CL, Bander NH and Albino AP: Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A. Proc Natl Acad Sci USA 1993; 90: 7069-7073.

58. Holt EH, Vasavada RC, Bander NH, Broadus AE and Philbrick WM: Region-specific methylation of the parathyroid hormone-related peptide gene determines its expression in human renal carcinoma cell lines. J Biol Chem 1993; 268: 20639-20645.

59. Gastl G, Bander NH, Frick J, Huber C and Aulitzky W: Immunotherapie des metastasierten nierenzellkarzinomas mit rekombinantem interferon-gamma. In: Immunotherapie in der Uroonkologie, Rubben H, Goepel M, Schmitz-Drager B, (eds). Springer-Verlag, Heidelberg, Germany 1993.

60. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh F-M, Lubensky I, Duan D-S R, Florence C, Pozzatti R, Walther MM, Bander NH et al.: VHL tumor suppressor gene mutations in renal cell carcinoma tumorigenesis. Nature Genet 1994; 7: 85-90.

61. Bander NH: Current status of monoclonal antibodies for imaging and therapy of prostate cancer. In: Seminars in Oncology, Scher H., (ed). WB Saunders, New York, NY 1994; 21.

62. Berger MF, Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, van Fleuren G, Oettgen HF and Old LJ: Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. In: Biology of Renal Cell Carcinoma, Bukowski RM, Finke JH, Klein EA, (eds). Springer-Verlag, New York, NY 1995.

63. Bander NH: Immunology of renal cancer. In: Comprehensive Textbook of Genitourinary Oncology, Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, (eds). Williams & Wilkins, Philadelphia, PA 1995.

64. Kinouchi T, Bander NH and Kotake T: Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement-dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity. J Urol 1995; 154: 288-292.

65. Aoyagi T, Bander NH: Cytotoxicity of gallium nitrate in vitro using bladder cancer cells. Int J Urol 1995; 2(5): 288-294.

66. Gastl G, Ebert T, Finstad CL, Sheinfeld J, Gomahr A, Aulitzky W and Bander NH:
MHC Class I and Class II expression in renal cell carcinoma and modulation by interferon-gamma. J Urol 1996; 155: 361-367.

67. Motzer RJ, Bander NH and Nanus DM: Renal cell carcinoma. N Engl J Med 1996; 335: 865-875.

68. Shemtov MM and Bander NH: Immunologic approaches to genitourinary malignancies. In Campbell?s Urology Update (Patrick C Walsh, Alan B Retik, Thomas A Stamey, E Darracott Vaughan and Alan J Wein, (eds) Philadelphia, PA. 20,1996.

69. McKiernan JM, Buttyan R, Bander NH, Stifelman MD, Katz AE, Chen M-W, Olsson CA and Sawczuk IS: Expression of the tumor-associated gene MN; a potential biomarker for human renal cell carcinoma. Cancer Res 1997; 57: 2362-2365.

70. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, Hanna Jr MG, Silberman SR and Butman BT: A multicenter trial evaluation of the Aura-Tek FDP test for detection and monitoring of bladder cancer. J Urol 1997; 158: 801-805.

71. Motzer RJ, Bander NH and Nanus DM: Letter to the Editor. N Engl J Med 1997;
336: 810-811.

72. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B and Bander NH: Monoclonal antibodies to the extracellular domain of prostate specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57: 3629-3634.

73. Bander NH, Yao D, Liu H, Chen Y-T, Steiner M, Zuccaro W and Moy P: MHC Class I and II expression in prostate carcinoma and modulation by interferon-alpha and
-gamma. The Prostate 1997; 33: 233-239.

74. Oosterwijk E, Bander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, Oettgen HF, and Old LJ: Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. Classic Papers and Current Comments 1997; 2: 331-344.

75. Bander NH, Cordon-Cardo C, Finstad CL, Whitmore WF Jr., Vaughan ED Jr., Oettgen HF, Melamed M, and Old LJ: Summary of Immunohistologic Dissection of the Human Kidney Using Monoclonal Antibodies. Seminars in Urol Oncol 1997; 15(2): 123-130.

76. Nanus DM, Bogenrieder T, Papandreou CN, Finstad CL, Lee A, Vlamis V, Motzer RJ, Bander NH, Albino AP, and Reuter VE: Aminopeptidase A expression and enzymatic activity in primary human renal cancers. Int J Oncology 1998; 13(2): 261-267.


77. Liu H, Rajasekaran A.K., Moy P., Xia Y., Kim S., Navarro V., Rahmati R., and
Bander NH: Constitutive and Antibody-Induced Internalization of Prostate Specific Membrane Antigen. Cancer Res 1998; 58: 4055-4060.

78. Divgi C.R., Bander NH, Scott A.M., O?Donoghue, Sgouros G, Welt S., Finn R.D., Morrissey F., Capitelli P., Williams J.M., Deland D., Nakhre A., Oosterwijk E., Gulec S., Graham M.C., Larson S.M., Old L.J.: Phase I/II radioimmunotherapy trial with iodine-131 labeled monoclonal antibody (mAb) G250 in metastatic renal carcinoma. Clin Cancer Res 1998;4: 2729-2739 .

79. Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, and Hicklin D.J.:
Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 1998; 4: 2957-2966.

80. Ebert T, Anastasiadis A, Bander NH: Renal Cell Cancer in Human Cell Culture JR.W. Masters and B. Palsson (eds). Kluwer Academic Publishers 1999.

81. Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, Molto L,
Tannenbaum C, Worford LJ, Bukowski R, Tubbs R, Hsi ED, Bander, NH, Novick AC, and Finke JH: Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 1999; 5: 1219-1229.

82. Kolenko V, Uzzo RG, Bukowski R, Bander NH, Novick AC, Finke JH: Dead or
dying: Necrosis vs. apoptosis in caspase deficient human renal cell carcinoma. Cancer Res, 1999,59: 2838-2842.

83. Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, and Gaudin PB: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59: 3192-3198.

84. Gong MC, Latouche JB, Krause A, Heston WDW, Bander NH & Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999; 1(2): 123-127 .

85. Rajasekaran SA, Ball WJ Jr, Bander NH., Liu H, Pardee JD, and Rajasekaren AK: Reduced expression of -subunit of Na,K-ATPase in human clear-cell renal cell carcinoma. J Urology, 1999; 162: 574-580.

86. Shirakawa T, Gardner TA, Ko S-C, Bander N, Woo S, Gotoh A, Kamidono S,
Chung LWK and Kao C: Cytotoxocity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. J Urology 1999; 162: 949-954.


87. Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V,
Gure AO, Jager D, Jager E, Knuth A, Chen YT and Old LJ: Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer 1999, 83(4): 456-464.

88. Chang SS, Bander NH, Heston WDW: Monoclonal Antibodies: Will they
become an integral part of the evaluation and treatment of prostate cancer-focus on prostate-specific membrane antigen. Current Opinion In Urology 1999; 9: 391-395.

89. Bander NH: Monoclonal antibodies for imaging and therapy of prostate cancer.
Klein E (ed). Management of Prostate Cancer. Humana Press, Totowa, NJ: 1999.

90. Gong MC, Chang SS, Sadelain M, Bander NH, Heston WDW: Prostate-specific
membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate cancer. Cancer Metastasis Rev 1999; 18: 483-90.

91. McKiernan JM, Buttyan R, Bander NH, de la Taille A, Stifelman MD, Emanuel ER, Bagiella E, Rubin MA, Katz AE, Olsson CA, Sawczuk IS: The detection of renal cancer cells in the peripheral blood via an enhanced RT-PCR assay for MN/CA9. Cancer, 1999; 86(3): 492-497.

92. Bander NH: Monoclonal antibodies in the diagnosis and treatment of renal
cancer. Vogelzang NJ et al (eds). Comprehensive Textbook of Genitourinary Oncology, Second Edition, Lippincott Williams & Wilkins, Philadelphia, PA, 1999.

93. Oosterwijk E, Divgi CR, Steffens MS and Bander NH: Monoclonal antibodies in
advanced renal cell carcinoma. Bukowski RM and Novick AC (eds). Renal Cell Carcinoma ? Molecular Biology, Immunology, and Clinical Management, Humana Press, Totowa, NJ: 2000.

94 Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ,
Bastidas D and Bander NH: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. Cancer Res, 2000; 60(18): 5237-5243.

95. McDevitt MR, Barendswaard E, Ma D, Curcio MJ, Lai L, Sgouros G, Ballangrud
AM, Yang W-H, Finn RD, Geerlings MW Jr, Brechbiel MW, Bander NH, and Scheinberg DA: An Alpha-particle emitting antibody ([213Bi]J591) for radioimmunology of prostate cancer. Cancer Res. 2000; 60: 6095-6100.


96. Gong MC, Chang SS, Watt F, O?Keefe DS, Bacich DJ, Uchida A, Bander
NH, Reuter VE, Gaudin PB, Molloy PL, Sadelain M, Heston WD: Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Mol Urol 2000 :4(3): 217-222.

97. de la Taille A; Cao Y, Sawczuk IS, Nozemu T, d?Agati V, McKiernan JM, Bagiella E, Buttyan R, Burchardt M, Olsson CA, Bander N, Katz AE: Detection of prostate-specific membrane antigen expressing cells in blood obtained from renal cancer patients: a potential biomarker of vascular invasion. Cancer Detect Prev) 2000, 24(6): 2008-2014.

98. Rajasekaran SA, Palmer LG, Ball WJ Jr, Bander NH, Alejandro Peralta Soler and Rajasekaran AK: Na,K-ATPase -subunit is required for epithelial polarization, suppression of invasion and cell motility. Mol Biol Cell 2001; 12: 279-295.

99. Goldsmith SJ, Bander NH: Prostate cancer: Monoclonal Antibody Therapy. Khalkhali I, Maublant JC, Goldsmith SJ (eds). Nuclear Oncology: Diagnosis and Therapy. Lippincott Williams & Wilkins, Philadelphia, 2001.

100. Ballangrud AM, Yang W-H, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D, Bander NH, Scheinberg DA and Sgouros G: Response of LNCaP spheroids after treatment with an -particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res 2001; 61: 2008-2014.

101. Divgi CR, Oosterwijk E, Bander NH, Welt S, Larson SM, Old L: Renal Carcinoma: Monoclonal Antibody Therapy. Khalkhali I, Maublant JC, Goldsmith SJ (eds). Nuclear Oncology: Diagnosis and Therapy. Lippincott Williams & Wilkins, Philadelphia, 2001.

102. Uzzo RG, Kolenko V, Froelich CJ, Tannenbaum C, Molto L, Novick AC, Bander NH, Bukowski R and Finke JH: The T cell death knell: Immune-mediate tumor death in renal cell carcinoma. Clin Cancer Res 2001; 7: 3276-3281.

103. Belldegrun A, Bander NH, Lerner SP, Wood DP, Pantuck AJ: Society of
Urologic Oncology Biotechnology Forum: New Approaches and Targets for Advanced Prostate Cancer. J Urol 2001; 166: 1316-1321.

104. McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank K, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg, DA.: Tumor Therapy with Targeted Atomic Nano-Generators. Science 2001; 294: 1537-1540.

105. Li Y, Tian Z, Rizvi S, Bander NH, Allen BJ: In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer and Prostatic Dis 2002; 5: 36-46.

106. Smith Jones MP, Vallabhajosula S, Navarro V, Goldsmith SJ and Bander NH: 90Y-huJ591 mAb specific to PSMA: radioimmunotherapy (RIT) studies in nude mice with prostate cancer LNCaP tumor. Eur J Nucl Med 2002; 8: 951.

107. Christiansen JJ, Rajasekaran SA, Moy P, Butch A, Goodglick, Gu Z, Reiter R, Bander NH, Rajasekaran AK: Polarity of prostate specific membrane antigen, prostate stem cell antigen and prostate specific antigen in prostate tissue in a cultured epithelial cell line. The Prostate 2003; 55: 9-19.

108. Anilkumar G, Rajasekaran S, Wong S, Hankinson O, Bander NH and Rajasekaran AK: Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALAdase activity. Cancer Res, 2003: 63: 2645-2648.

109. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ and Bander NH: Radiolabeled monoclonal antibodies specific to the extra-cellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nuc Med, 2003; 44: 610-617.

110. Nanus D, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ and Bander NH: Clinical use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane Antigen. J Urol, 2003:170: S84-S89.

111. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, Bander NH, Rajasekaran AK: A novel cytoplasmic tail MXXXL motif mediates the internalization and lysosomal targeting of prostate specific membrane antigen. Molecular & Cell Biology, 2003:14: 4835-4845.

112. Bander, NH, Trabulsi E, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM and Goldsmith SJ: Targeting Metastatic Prostate Cancer with Radiolabeled Monoclonal Antibody J591 in the Extracellular Domain of Prostate Specific Membrane Antigen. J Urol, 2003; 170: 1717-1721.

113. Bander, NH, Nanus, D.M., Milowsky, M.I., Kostakoglu, L., Vallabahajosula, S., and Goldsmith, S.J.: Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate specific membrane antigen (PSMA). Seminars in Oncology, 2003; 30: 667-676.

114. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W., Bander NH, and Rajasekaran AK.: A Novel Cytoplastic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen. Mol Bio Cell 2003; 14: 4835-4845.

115. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ and Bander NH: Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice. The Prostate, 2004: 58: 145-155.


117. Milowsky M.I., Nanus D.M., Kostakoglu L., Vallabhajosula S, Goldsmith S.J., and Bander NH: Phase I Trial Results of Yttrium-90 Labeled Anti-Prostate Specific Membrane Antigen Monoclonal Antibody J591 in the Treatment of Patients with Recurrent Prostate Cancer. J Clin Onc, 2004; 22: 2522-2531.

118. Patri AK, Myc A, Beals, J, Thomas TP, Bander NH, Baker JR: Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem, 2004; 15: 1174-1181.

119. Christiansen JJ, Rajasekaran SA, Weimbs T, Gopalakrishna A, Bander NH and Rajasekaran AK.: Apical targeting of prostate specific membrane antigen requires an N-glycosylation sorting signal and microtubule dependent localization of syntaxin 3. Mol.Bio.Cell, 2004.

120. Konishi S, Hamacher K, Vallabhajosula S, Kothari P, Bastidas D, Bander NH, Goldsmith S: Determination of immunoreavtive fraction of radiolabeled monoclonal antibodies: what is an appropriate method? Cancer Biother Radiophar 2004; 19: 706-715.

121. Kelly JD, Dai J, Eschwege P, Goldbreg JS, Duggan BP, Williamson KE, Bander NH, Nanus DM: Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas. Br J Cancer 2004; 91: 164-170.


122. Bander NH: Editorial ?Novel Therapy for PSA Progression in Absence of Imagable Disease Following Local Therapy. Cummings, K., (ed). Management of Prostate Cancer: Advances and Controversies. Marcel Dekker, Inc, New York, NY: 2005.

123. Bander NH, Milowsky M.I., Nanus D.M., Kostakoglu L., Vallabhajosula S, and Goldsmith S.J.: Phase I Trial Results of 177Lutetium-Labeled Anti-Prostate Specific Membrane-Antigen Monoclonal Antibody J591 in the Treatment of Patients with Recurrent Prostate Cancer. J Clin Onc, in press 2005.


124. Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA,
Milowsky MI. Nanus DM, Bander NH an Goldsmith SJ: Pharmacokinetics and
Biodistribution of 111IN and 177Lu Labeled J591 Antibody Specific to Prostate Specific
Membrane Antigen Prediction of 90Y-J591 Radiation Dosimetry Based on 111In and
177Lu. J Nuc Med, in press, 2005.

125. Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowsky
MI, Nanus DM and Bander NH: Prediction of Myelotoxicity Based on Bone Marrow Radiation Absorbed Dose: Radioimmunotherapy Studies using 90Y and 177Lu labeled J591 Antibodies Specific to Prostate Specific Membrane Antigen (PSMA). , J Nuc Med, in press, 2005.

126. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM and
Bander NH: Radioimmunotherapy of Prostate Cancer Using 90Y ad 177Lu Labeled
J591 Monoclonal Antibodies: Effect of Dose Fractionation and Multiple Treatments
on Myelotoxocity. Clin Cancer Res (suppl) in press, 2005.

127. Palm S, Emmon, R M Jr, Yang, W-H, Bander N, McDevitt MR, Scheinberg DA, Scher HI, and Sgouros G, Microdosimetric analysis of spheroid response to alpha-emitter labeled anti-PSMA antibody (225Ac-J591): Modeling the targeting of prostate micrometastases. Submitted.

128. Ross JS, Gray, KE, Webb I, Gray GS, Rolfe M, Schenkein DP, Nanus DM, Milowsky MI, Bander NH: PSMA and Other Cell Surface Protein Targets For Antibody-Based Immunotherapy for Prostate Cancer, Ross J (ed). Molecular Oncol of Prostate Cancer. Jones & Bartlett, Boston, MA., in press.

129. Ross JS, Gray KE, Webb I, Gray GS, Rolfe M, Schenkein DP, Nanus DM, Milowsky MI, Bander NH: Antibody-Based Therapeutics: Focus on Prostate Cancer. Cancer & Metastasis Reviews in press, May 2005.



U.S. Patents Issued:

1. United States Patent 4,713,352
Dec. 15, 1987

Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma

Inventors:
Bander, Neil H.; Whitmore, Willet F.; Old, Lloyd J.

Assignee: Sloan-Kettering Institute for Cancer Research.
_________________________________________________________

2. United States Patent 4,935,344
Jun. 19, 1990

Method for characterizing types of renal carcinoma and prognosis

Inventors:
Bander; Neil H.; Cordon-Cardo, Carlos; Finstad, Connie L.; Whitmore, Willet F.; Melamed, Myron R.; Oettgen, Herbert F., Old; Lloyd J.

Assignee: Sloan-Kettering Institute for Cancer Research.


3. United States Patent 5,145,773
Sept. 8, 1992

Method to detect sensitivity to alpha-interferon therapy

Inventors:
Albino, Anthony P.; Nanus, David M.; Bander, Neil H.; Pfeffer Lawrence M..

Assignee: Sloan-Kettering Institute for Cancer Research. _________________________________________________________________________

4. United States Patent 5,773,292
June 30, 1998

Antibodies, binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood

Inventors:
Bander, Neil H.

Assignee: Cornell University.
______________________________________________________






5. United States Patent 6,087,098
July 11, 2000

Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma

Inventors:
McKiernan, James M.; Sawczuk, Ihor S.; Buttyan, Ralph; Bander, Neil H..

Assignee:
The Trustees of Columbia University in the City of New York; Cornell Research Foundation, Inc.
_______________________________________________________
6. United States Patent 6,107,090
August 22, 2000

Treatment and diagnosis of prostate cancer with antibodies to extracellular PSMA domains

Inventor:
Bander, Neil H.

Assignee:
Cornell Research Foundation, Inc.
_______________________________________________________________________
7. United States patent 6,136,311
October 24, 2000

Treatment and Diagnosis of Cancer.

Inventor:
Bander, Neil H.

Assignee:
Cornell Research Foundation, Inc.



8. United States patent 6,299,598
October 9, 2001

Postprostatectomy suprapubic drainage catheter

Inventor:
Bander, Neil H.

Assignee: Cook Urological, Inc.


9. United States patent 6,451,532
September 17, 2002

Enhanced reverse transcriptase polymerase chain assay to detect MN antigen in patients with renal cell carcinoma

Inventor:
McKiernan, James M.; Sawczuk, Ihor S.; Buttyan, Ralph; Bander, Neil H.

The Trustees of Columbia University in the City of New York; Cornell Research Foundation, Inc.

______________________________________________________________________________
10. United States patent 6,649,163
November 18, 2003

Treatment and Diagnosis of Cancer

Inventor:
Bander, N.H.

Assignee:
Cornell Research Foundation, Inc.

______________________________________________________________________________11. United States patent 6,653,129
November 25, 2003

Methods for the Isolation of Prostatic Epithelial Cells from a Biological Fluid

Inventors:
Bander, N.H., Glode, M.L. and Suh, C.I.

Assignee: University of Colorado


12, EurAsia and Eastern Europe patent 004634
June 24, 2004

Treatment and diagnosis of cancer

Inventor:
Bander, N.H. (US)

Assignee: Cornell Research Foundation, Inc.





13. United States patent 6,767,711
July 27, 2004

Treatment and diagnosis of prostate cancer

Inventor:
Bander, N.H.

Assignee:
Cornell Research Foundation, Inc.

14..United States patent 6,770,450
August 3, 2004

Treatment and diagnosis of cancer

Inventor:
Bander, N.H.

Assignee:
Cornell Research Foundation, Inc.

15, China patent 1165764
September 8, 2004

Treatment and Diagnosis of Cancer

Inventor:
Bander, N.H.

Assignee:
Cornell Research Foundation, Inc.


16. Israel patent 127979
February 25, 2005

Antibodies and Antigen Binding Portions Thereof That Bind Prostate Specific Membrane Antigen (PSMA) And Uses Thereof For Diagnosing Cancer

Inventor:
Bander, N.H.

Assignee:
Cornell Research Foundation, Inc.